SEALANT

  • Research type

    Research Study

  • Full title

    SEALANT: Safety and Effectiveness Analysis of stent assisted coiling with LVIS® Evo™ and HydroCoil® Embolic System in ANeurysm Treatment

  • IRAS ID

    303268

  • Contact name

    Jonathan Downer

  • Contact email

    jonny.downer@nhslothian.scot.nhs.uk

  • Sponsor organisation

    MicroVention Europe

  • Clinicaltrials.gov Identifier

    NCT04999423

  • Duration of Study in the UK

    4 years, 5 months, 1 days

  • Research summary

    This is an observational study. Treatments and follow-up visits will be done as per standard of care. There are no additional procedures or tests.
    The objective of this study is to demonstrate that use of stent-assisted coiling using LVIS® Evo™ and HydroCoil® Embolic System (HES) in intracranial aneurysm treatment is effective and safe when assessed at 1 year after the procedure.
    Both devices are CE-marked and will be used in their approved indication.
    It is planned to includ approximately 200 patients in up to 20 sites in the UK and EU countries. Patients presenting with an unruptured or ruptured (> 30 days since occurrence) intracranial aneurysm eligible for endovascular treatment using LVIS® Evo™ and HydroCoil® Embolic System (HES) are eligible for this study.
    The expected approximate study duration is 54 months, wtih an 18 months enrollment period and up to 36 months of follow-up period.
    As this is an observational study with no additional procedures to standard of care, only patients medical data will be collected.

  • REC name

    West of Scotland REC 5

  • REC reference

    21/WS/0127

  • Date of REC Opinion

    19 Nov 2021

  • REC opinion

    Further Information Favourable Opinion